Aura Biosciences, Inc. is the issuer covered by this Schedule 13G/A filed by multiple Frazier Life Sciences entities and individuals. The filing shows that Frazier Life Sciences Public Fund, L.P. directly holds 3,113,550 shares of Aura common stock, reported as 5.0% of the class based on the issuer's reported outstanding share counts used in the filing.
The statement also discloses additional direct holdings across related Frazier vehicles: 918,510 shares by the Public Overage Fund, 128,520 by FLS X, 342,210 by FLS XI and 597,210 by FLS XII. Several prefunded warrants are listed (for example, 778,388 warrants held by FLSPF), each subject to a 9.99% beneficial ownership exercise limit. The filing corrects prior attributions to certain investment-committee members and clarifies which entities directly hold the securities.
Aura Biosciences, Inc. è l'emittente oggetto di questo Schedule 13G/A depositato da più entità e persone di Frazier Life Sciences. Il documento indica che Frazier Life Sciences Public Fund, L.P. detiene direttamente 3,113,550 azioni ordinarie di Aura, segnalate come 5.0% della classe sulla base del numero di azioni in circolazione comunicato dall'emittente e utilizzato nel deposito.
La dichiarazione rende inoltre note partecipazioni dirette aggiuntive tra veicoli correlati di Frazier: 918,510 azioni dal Public Overage Fund, 128,520 da FLS X, 342,210 da FLS XI e 597,210 da FLS XII. Sono elencati diversi warrant prefinanziati (ad esempio, 778,388 warrant detenuti da FLSPF), ciascuno soggetto a un limite di esercizio pari al 9.99% di partecipazione beneficiaria. Il deposito corregge attribuzioni precedenti a certi membri del comitato di investimento e chiarisce quali entità detengono direttamente i titoli.
Aura Biosciences, Inc. es el emisor al que se refiere este Schedule 13G/A presentado por varias entidades y personas de Frazier Life Sciences. La presentación muestra que Frazier Life Sciences Public Fund, L.P. posee directamente 3,113,550 acciones ordinarias de Aura, reportadas como 5.0% de la clase con base en el número de acciones en circulación informado por el emisor y utilizado en la presentación.
La declaración también revela participaciones directas adicionales en vehículos relacionados de Frazier: 918,510 acciones del Public Overage Fund, 128,520 de FLS X, 342,210 de FLS XI y 597,210 de FLS XII. Se listan varios warrants prefunded (por ejemplo, 778,388 warrants en poder de FLSPF), cada uno sujeto a un límite de ejercicio del 9.99% de propiedad beneficiaria. La presentación corrige atribuciones previas a ciertos miembros del comité de inversión y aclara qué entidades poseen los valores de forma directa.
Aura Biosciences, Inc.는 본 Schedule 13G/A의 대상 발행인으로, 여러 Frazier Life Sciences 계열 법인과 개인이 이를 제출했습니다. 제출서에 따르면 Frazier Life Sciences Public Fund, L.P.는 Aura 보통주를 직접 3,113,550주 보유하고 있으며, 이는 제출서에 사용된 발행인의 보고된 유통주수를 기준으로 클래스의 5.0%로 기재되어 있습니다.
보고서는 또한 관련 Frazier 계열사들에서의 추가 직접 보유를 공개합니다: Public Overage Fund가 918,510주, FLS X가 128,520주, FLS XI가 342,210주, FLS XII가 597,210주를 보유하고 있습니다. 여러 건의 사전충전(prefunded) 워런트가 기재되어 있으며(예: FLSPF가 보유한 778,388 워런트), 각 워런트에는 9.99%의 실질 소유권 행사 한도가 적용됩니다. 이 제출서는 일부 투자위원회 구성원에 대한 이전 귀속을 정정하고, 어떤 법인이 증권을 직접 보유하는지 명확히 밝혔습니다.
Aura Biosciences, Inc. est l'émetteur visé par ce Schedule 13G/A déposé par plusieurs entités et personnes de Frazier Life Sciences. Le document indique que Frazier Life Sciences Public Fund, L.P. détient directement 3,113,550 actions ordinaires d'Aura, déclarées comme représentant 5.0% de la classe sur la base du nombre d'actions en circulation communiqué par l'émetteur et utilisé dans le dépôt.
La déclaration révèle également des participations directes supplémentaires au sein d'autres véhicules Frazier : 918,510 actions par le Public Overage Fund, 128,520 par FLS X, 342,210 par FLS XI et 597,210 par FLS XII. Plusieurs bons de souscription préfinancés sont mentionnés (par exemple 778,388 warrants détenus par FLSPF), chacun soumis à une limite d'exercice de 9.99% de détention bénéficiaire. Le dépôt corrige des attributions antérieures à certains membres du comité d'investissement et précise quelles entités détiennent directement les titres.
Aura Biosciences, Inc. ist der Emittent, auf den sich dieses Schedule 13G/A bezieht, das von mehreren Frazier Life Sciences-Einheiten und Einzelpersonen eingereicht wurde. Die Einreichung zeigt, dass Frazier Life Sciences Public Fund, L.P. direkt 3,113,550 Aktien von Aura-Stammaktien hält, ausgewiesen als 5.0% der Klasse basierend auf den vom Emittenten gemeldeten ausstehenden Aktienzahlen, die in der Meldung verwendet wurden.
Die Erklärung legt außerdem zusätzliche direkte Bestände über verbundene Frazier-Fahrzeuge offen: 918,510 Aktien vom Public Overage Fund, 128,520 von FLS X, 342,210 von FLS XI und 597,210 von FLS XII. Mehrere vorab finanzierte Warrants sind aufgeführt (zum Beispiel 778,388 Warrants im Besitz von FLSPF), jeweils mit einer Ausübungsbegrenzung von 9.99% der wirtschaftlichen Eigentümerschaft. Die Einreichung korrigiert frühere Zuschreibungen an bestimmte Mitglieder des Investitionsausschusses und macht deutlich, welche Einheiten die Wertpapiere direkt halten.
Positive
Clear disclosure of a 5.0% direct stake by Frazier Life Sciences Public Fund, L.P. (3,113,550 shares), which notifies the market of a material holder
Detailed breakdown of related entity holdings (918,510; 128,520; 342,210; 597,210 shares) improves transparency about aggregate Frazier exposure
Disclosure of prefunded warrants with explicit 9.99% exercise limits provides clarity on potential dilution and prevents surprise conversions above the stated threshold
Correction of prior attributions clarifies that certain investment-committee members are not individually attributed beneficial ownership, improving accuracy of public records
Negative
None.
Insights
TL;DR: Routine institutional Schedule 13G/A disclosing a 5.0% stake by a Frazier vehicle with related entity holdings and prefunded warrants.
The filing is a standard beneficial-ownership disclosure showing that Frazier Life Sciences Public Fund, L.P. holds 3,113,550 shares, representing 5.0% of Aura's common stock using the disclosed outstanding-share base. Related Frazier funds hold additional, smaller positions and disclosed prefunded warrants with explicit exercise limits at 9.99%, which prevents immediate conversion into large additional stakes. The correction of prior attributions reduces ambiguity about which individuals are deemed to hold voting or dispositive power. For investors, this is material as a transparency and ownership update but is procedural rather than a strategic change of control.
TL;DR: Clarifies beneficial ownership and corrects prior attribution errors; improves governance transparency without indicating control intent.
The amendment explicitly rescinds previous attributions to certain investment-committee members for several funds, clarifying that voting and dispositive power rests with the named entities. That reduces potential misstatements about individual influence. The filing's certification reiterates that holdings were not acquired to influence control. From a governance perspective, the disclosure enhances accuracy around who exercises investment power, which is important for board and shareholder oversight but does not itself signal a governance dispute or coordination among holders.
Aura Biosciences, Inc. è l'emittente oggetto di questo Schedule 13G/A depositato da più entità e persone di Frazier Life Sciences. Il documento indica che Frazier Life Sciences Public Fund, L.P. detiene direttamente 3,113,550 azioni ordinarie di Aura, segnalate come 5.0% della classe sulla base del numero di azioni in circolazione comunicato dall'emittente e utilizzato nel deposito.
La dichiarazione rende inoltre note partecipazioni dirette aggiuntive tra veicoli correlati di Frazier: 918,510 azioni dal Public Overage Fund, 128,520 da FLS X, 342,210 da FLS XI e 597,210 da FLS XII. Sono elencati diversi warrant prefinanziati (ad esempio, 778,388 warrant detenuti da FLSPF), ciascuno soggetto a un limite di esercizio pari al 9.99% di partecipazione beneficiaria. Il deposito corregge attribuzioni precedenti a certi membri del comitato di investimento e chiarisce quali entità detengono direttamente i titoli.
Aura Biosciences, Inc. es el emisor al que se refiere este Schedule 13G/A presentado por varias entidades y personas de Frazier Life Sciences. La presentación muestra que Frazier Life Sciences Public Fund, L.P. posee directamente 3,113,550 acciones ordinarias de Aura, reportadas como 5.0% de la clase con base en el número de acciones en circulación informado por el emisor y utilizado en la presentación.
La declaración también revela participaciones directas adicionales en vehículos relacionados de Frazier: 918,510 acciones del Public Overage Fund, 128,520 de FLS X, 342,210 de FLS XI y 597,210 de FLS XII. Se listan varios warrants prefunded (por ejemplo, 778,388 warrants en poder de FLSPF), cada uno sujeto a un límite de ejercicio del 9.99% de propiedad beneficiaria. La presentación corrige atribuciones previas a ciertos miembros del comité de inversión y aclara qué entidades poseen los valores de forma directa.
Aura Biosciences, Inc.는 본 Schedule 13G/A의 대상 발행인으로, 여러 Frazier Life Sciences 계열 법인과 개인이 이를 제출했습니다. 제출서에 따르면 Frazier Life Sciences Public Fund, L.P.는 Aura 보통주를 직접 3,113,550주 보유하고 있으며, 이는 제출서에 사용된 발행인의 보고된 유통주수를 기준으로 클래스의 5.0%로 기재되어 있습니다.
보고서는 또한 관련 Frazier 계열사들에서의 추가 직접 보유를 공개합니다: Public Overage Fund가 918,510주, FLS X가 128,520주, FLS XI가 342,210주, FLS XII가 597,210주를 보유하고 있습니다. 여러 건의 사전충전(prefunded) 워런트가 기재되어 있으며(예: FLSPF가 보유한 778,388 워런트), 각 워런트에는 9.99%의 실질 소유권 행사 한도가 적용됩니다. 이 제출서는 일부 투자위원회 구성원에 대한 이전 귀속을 정정하고, 어떤 법인이 증권을 직접 보유하는지 명확히 밝혔습니다.
Aura Biosciences, Inc. est l'émetteur visé par ce Schedule 13G/A déposé par plusieurs entités et personnes de Frazier Life Sciences. Le document indique que Frazier Life Sciences Public Fund, L.P. détient directement 3,113,550 actions ordinaires d'Aura, déclarées comme représentant 5.0% de la classe sur la base du nombre d'actions en circulation communiqué par l'émetteur et utilisé dans le dépôt.
La déclaration révèle également des participations directes supplémentaires au sein d'autres véhicules Frazier : 918,510 actions par le Public Overage Fund, 128,520 par FLS X, 342,210 par FLS XI et 597,210 par FLS XII. Plusieurs bons de souscription préfinancés sont mentionnés (par exemple 778,388 warrants détenus par FLSPF), chacun soumis à une limite d'exercice de 9.99% de détention bénéficiaire. Le dépôt corrige des attributions antérieures à certains membres du comité d'investissement et précise quelles entités détiennent directement les titres.
Aura Biosciences, Inc. ist der Emittent, auf den sich dieses Schedule 13G/A bezieht, das von mehreren Frazier Life Sciences-Einheiten und Einzelpersonen eingereicht wurde. Die Einreichung zeigt, dass Frazier Life Sciences Public Fund, L.P. direkt 3,113,550 Aktien von Aura-Stammaktien hält, ausgewiesen als 5.0% der Klasse basierend auf den vom Emittenten gemeldeten ausstehenden Aktienzahlen, die in der Meldung verwendet wurden.
Die Erklärung legt außerdem zusätzliche direkte Bestände über verbundene Frazier-Fahrzeuge offen: 918,510 Aktien vom Public Overage Fund, 128,520 von FLS X, 342,210 von FLS XI und 597,210 von FLS XII. Mehrere vorab finanzierte Warrants sind aufgeführt (zum Beispiel 778,388 Warrants im Besitz von FLSPF), jeweils mit einer Ausübungsbegrenzung von 9.99% der wirtschaftlichen Eigentümerschaft. Die Einreichung korrigiert frühere Zuschreibungen an bestimmte Mitglieder des Investitionsausschusses und macht deutlich, welche Einheiten die Wertpapiere direkt halten.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
Aura Biosciences, Inc.
(Name of Issuer)
Common Stock, $0.00001 par value per share
(Title of Class of Securities)
05153U107
(CUSIP Number)
06/30/2025
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
SCHEDULE 13G
CUSIP No.
05153U107
1
Names of Reporting Persons
Frazier Life Sciences Public Fund, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,113,550.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,113,550.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,113,550.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.0 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement.
The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, and (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025.
SCHEDULE 13G
CUSIP No.
05153U107
1
Names of Reporting Persons
FHMLSP, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,113,550.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,113,550.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,113,550.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.0 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement.
The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, and (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025.
SCHEDULE 13G
CUSIP No.
05153U107
1
Names of Reporting Persons
FHMLSP, L.L.C.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,113,550.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,113,550.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,113,550.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.0 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement.
The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, and (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025.
SCHEDULE 13G
CUSIP No.
05153U107
1
Names of Reporting Persons
Frazier Life Sciences Public Overage Fund, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
918,510.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
918,510.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
918,510.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.5 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement.
The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, and (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025.
SCHEDULE 13G
CUSIP No.
05153U107
1
Names of Reporting Persons
FHMLSP Overage, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
918,510.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
918,510.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
918,510.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.5 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement.
The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, and (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025.
SCHEDULE 13G
CUSIP No.
05153U107
1
Names of Reporting Persons
FHMLSP Overage, L.L.C.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
918,510.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
918,510.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
918,510.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.5 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement.
The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, and (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025.
SCHEDULE 13G
CUSIP No.
05153U107
1
Names of Reporting Persons
Frazier Life Sciences X, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
128,520.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
128,520.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
128,520.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.2 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement.
The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, and (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025.
SCHEDULE 13G
CUSIP No.
05153U107
1
Names of Reporting Persons
FHMLS X, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
128,520.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
128,520.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
128,520.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.2 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement.
The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, and (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025.
SCHEDULE 13G
CUSIP No.
05153U107
1
Names of Reporting Persons
FHMLS X, L.L.C.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
128,520.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
128,520.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
128,520.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.2 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement.
The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, and (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025.
SCHEDULE 13G
CUSIP No.
05153U107
1
Names of Reporting Persons
Frazier Life Sciences XI, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
342,210.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
342,210.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
342,210.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.6 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement.
The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, and (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025.
SCHEDULE 13G
CUSIP No.
05153U107
1
Names of Reporting Persons
FHMLS XI, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
342,210.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
342,210.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
342,210.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.6 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement.
The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, and (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025.
SCHEDULE 13G
CUSIP No.
05153U107
1
Names of Reporting Persons
FHMLS XI, L.L.C.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
342,210.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
342,210.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
342,210.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.6 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement.
The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, and (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025.
SCHEDULE 13G
CUSIP No.
05153U107
1
Names of Reporting Persons
Frazier Life Sciences XII, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
597,210.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
597,210.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
597,210.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.0 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement.
The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, and (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025.
SCHEDULE 13G
CUSIP No.
05153U107
1
Names of Reporting Persons
FHMLS XII, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
597,210.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
597,210.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
597,210.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.0 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement.
The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, and (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025.
SCHEDULE 13G
CUSIP No.
05153U107
1
Names of Reporting Persons
FHMLS XII, L.L.C.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
597,210.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
597,210.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
597,210.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.0 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement.
The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, and (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025.
SCHEDULE 13G
CUSIP No.
05153U107
1
Names of Reporting Persons
James N. Topper
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
128,520.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
128,520.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
128,520.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.2 %
12
Type of Reporting Person (See Instructions)
IN
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held directly by Frazier Life Sciences X, L.P. and do not include any warrants held directly by Frazier Life Sciences X, L.P. See item 4(a) to this Statement.
The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, and (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025.
SCHEDULE 13G
CUSIP No.
05153U107
1
Names of Reporting Persons
Patrick J. Heron
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
128,520.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
128,520.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
128,520.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.2 %
12
Type of Reporting Person (See Instructions)
IN
Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held directly by Frazier Life Sciences X, L.P. and do not include any warrants held directly by Frazier Life Sciences X, L.P. See item 4(a) to this Statement.
The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, and (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025.
SCHEDULE 13G
CUSIP No.
05153U107
1
Names of Reporting Persons
Albert Cha
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
0.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.0 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
CUSIP No.
05153U107
1
Names of Reporting Persons
James Brush
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
0.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.0 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
CUSIP No.
05153U107
1
Names of Reporting Persons
Daniel Estes
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
0.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.0 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Aura Biosciences, Inc.
(b)
Address of issuer's principal executive offices:
80 Guest Street, Boston, MA, 02135.
Item 2.
(a)
Name of person filing:
The entities and persons filing this statement (collectively, the "Reporting Persons") are:
Frazier Life Sciences Public Fund, L.P. ("FLSPF")
FHMLSP, L.P. FHMLSP, L.L.C.
Frazier Life Sciences Public Overage Fund, L.P. ("FLSPOF")
FHMLSP Overage, L.P.
FHMLSP Overage, L.L.C.
Frazier Life Sciences X, L.P. ("FLS X")
FHMLS X, L.P.
FHMLS X, L.L.C.
Frazier Life Sciences XI, L.P. ("FLS XI")
FHMLS XI, L.P.
FHMLS XI, L.L.C.
Frazier Life Sciences XII, L.P. ("FLS XII")
FHMLS XII, L.P.
FHMLS XII, L.L.C.
James N. Topper ("Topper")
Patrick J. Heron ("Heron")
Albert Cha ("Cha")
James Brush ("Brush")
Daniel Estes ("Estes" and together with Topper, Heron, Cha and Brush, the "Members")
(b)
Address or principal business office or, if none, residence:
The address of the principal place of business for each of the Reporting Persons is:
c/o Frazier Life Sciences Management, L.P.
1001 Page Mill Rd, Building 4, Suite B
Palo Alto, CA 94304
(c)
Citizenship:
The information contained in row 4 of each Reporting Person's cover page to this Statement is incorporated by reference.
(d)
Title of class of securities:
Common Stock, $0.00001 par value per share
(e)
CUSIP No.:
05153U107
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information contained in row 9 of each Reporting Person's cover page to this Statement (including the footnotes thereto) is incorporated by reference.
FLSPF directly holds 3,113,550 shares of Common Stock. FHMLSP, L.P. is the general partner of FLSPF and the general partner of FHMLSP, L.P. is FHMLSP, L.L.C., which is managed by an investment committee of four that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLSPF, and this Statement corrects any previous attribution to, and overstatement of beneficial ownership by, such members as reflected in any prior Statements.
FLSPOF directly holds 918,510 shares of Common Stock. FHMLSP Overage, L.P. is the general partner of FLSPOF and the general partner of FHMLSP Overage, L.P. is FHMLSP Overage, L.L.C., which is managed by an investment committee of four that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLSPOF, and this Statement corrects any previous attribution to, and overstatement of beneficial ownership by, such members as reflected in any prior Statements.
FLS X directly holds 128,520 shares of Common Stock. FHMLS X, L.P. is the general partner of FLS X and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Heron and Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares of Common Stock held by FLS X.
FLS XI directly holds 342,210 shares of Common Stock. FHMLS XI, L.P. is the general partner of FLS XI and the general partner of FHMLS XI, L.P. is FHMLS XI, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XI, and this Statement corrects any previous attribution to, and overstatement of beneficial ownership by, such members as reflected in any prior Statements.
FLS XII directly holds 597,210 shares of Common Stock. FHMLS XI, L.P. is the general partner of FLS XII and the general partner of FHMLS XII, L.P. is FHMLS XII, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XII, and this Statement corrects any previous attribution to, and overstatement of beneficial ownership by, such members as reflected in any prior Statements.
The above referenced beneficial ownership and amounts reflected on the cover pages hereto do not include certain prefunded warrants to acquire shares of Common Stock (the "Warrants"), the exercise of which is subject to certain beneficial ownership limitations. In this regard, (i) FLSPF holds Warrants to purchase 778,388 shares of Common Stock, (Ii) FLSPOF holds Warrants to purchase 229,628 shares of Common Stock, (iii) FLS X holds Warrants to purchase 32,130 shares of Common Stock, (iv) FLS XI holds Warrants to purchase 85,552 shares of Common Stock and (v) FLS XII holds Warrants to purchase 149,302 shares of Common Stock, each of which cannot be exercised, if, upon giving effect to such exercise, the aggregate number of shares of Common Stock beneficially owned by the holder of such Warrant (together with its affiliates or any other persons acting as a group together with such holder) would exceed 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.
Except as specifically stated herein, the filing of this Statement shall not be construed as an admission that any Reporting Person or any of the foregoing is, for the purposes of Section 13(d) and/or Section 13(g) of the Act or otherwise, the beneficial owner of any securities covered by this Statement or a member of a "group" with any other person.
(b)
Percent of class:
The information contained in row 11 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information contained in row 5 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.
(ii) Shared power to vote or to direct the vote:
The information contained in row 6 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.
(iii) Sole power to dispose or to direct the disposition of:
The information contained in row 7 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.
(iv) Shared power to dispose or to direct the disposition of:
The information contained in row 8 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.
Item 5.
Ownership of 5 Percent or Less of a Class.
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Frazier Life Sciences Public Fund, L.P.
Signature:
/s/ Steve R. Bailey
Name/Title:
By Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P.
Date:
08/14/2025
FHMLSP, L.P.
Signature:
/s/ Steve R. Bailey
Name/Title:
By Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P.
Date:
08/14/2025
FHMLSP, L.L.C.
Signature:
/s/ Steve R. Bailey
Name/Title:
By Steve R. Bailey, CFO of FHMLSP, L.L.C.
Date:
08/14/2025
Frazier Life Sciences Public Overage Fund, L.P.
Signature:
/s/ Steve R. Bailey
Name/Title:
By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C., GP of FHMLSP Overage, L.P., GP of Frazier Life Sciences Public Overage Fund, L.P.
Date:
08/14/2025
FHMLSP Overage, L.P.
Signature:
/s/ Steve R. Bailey
Name/Title:
By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C., GP of FHMLSP Overage, L.P.
Date:
08/14/2025
FHMLSP Overage, L.L.C.
Signature:
/s/ Steve R. Bailey
Name/Title:
By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C.
Date:
08/14/2025
Frazier Life Sciences X, L.P.
Signature:
/s/ Steve R. Bailey
Name/Title:
By Steve R. Bailey, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P., GP of Frazier Life Sciences X, L.P.
Date:
08/14/2025
FHMLS X, L.P.
Signature:
/s/ Steve R. Bailey
Name/Title:
By Steve R. Bailey, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P.
Date:
08/14/2025
FHMLS X, L.L.C.
Signature:
/s/ Steve R. Bailey
Name/Title:
By Steve R. Bailey, CFO of FHMLS X, L.L.C.
Date:
08/14/2025
Frazier Life Sciences XI, L.P.
Signature:
/s/ Steve R. Bailey
Name/Title:
By Steve R. Bailey, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P., GP of Frazier Life Sciences XI, L.P.
Date:
08/14/2025
FHMLS XI, L.P.
Signature:
/s/ Steve R. Bailey
Name/Title:
By Steve R. Bailey, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P.
Date:
08/14/2025
FHMLS XI, L.L.C.
Signature:
/s/ Steve R. Bailey
Name/Title:
By Steve R. Bailey, CFO of FHMLS XI, L.L.C.
Date:
08/14/2025
Frazier Life Sciences XII, L.P.
Signature:
/s/ Gordon Empey
Name/Title:
By Gordon Empey, General Counsel of FHMLS XII, L.L.C., GP of FHMLS XII, L.P., GP of Frazier Life Sciences XII, L.P.
Date:
08/14/2025
FHMLS XII, L.P.
Signature:
/s/ Gordon Empey
Name/Title:
By Gordon Empey, General Counsel of FHMLS XII, L.L.C., GP of FHMLS XII, L.P.
Date:
08/14/2025
FHMLS XII, L.L.C.
Signature:
/s/ Gordon Empey
Name/Title:
By Gordon Empey, General Counsel of FHMLS XII, L.L.C.
Date:
08/14/2025
James N. Topper
Signature:
/s/ Steve R. Bailey
Name/Title:
By Steve R. Bailey, Attorney-in-Fact for James N. Topper, pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017
Date:
08/14/2025
Patrick J. Heron
Signature:
/s/ Steve R. Bailey
Name/Title:
By Steve R. Bailey, Attorney-in-Fact for Patrick J. Heron, pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017
Date:
08/14/2025
Albert Cha
Signature:
/s/ Steve R. Bailey
Name/Title:
By Steve R. Bailey, Attorney-in-Fact for Albert Cha, pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021
Date:
08/14/2025
James Brush
Signature:
/s/ Steve R. Bailey
Name/Title:
By Steve R. Bailey, Attorney-in-Fact for James Brush, pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021
Date:
08/14/2025
Daniel Estes
Signature:
/s/ Steve R. Bailey
Name/Title:
By Steve R. Bailey, Attorney-in-Fact for Daniel Estes, pursuant to a Power of Attorney, a copy of which was filed with the SEC on April 18, 2022
Date:
08/14/2025
Exhibit Information
Exhibit 99.1 Joint Filing Agreement, dated as of May 23, 2025, incorporated by reference into this Statement.
What stake did Frazier Life Sciences Public Fund, L.P. report in Aura Biosciences (AURA)?
The filing shows 3,113,550 shares held directly by Frazier Life Sciences Public Fund, L.P., reported as 5.0% of the class.
Do Frazier entities hold additional Aura shares across related funds?
Yes. The filing lists additional direct holdings: 918,510 (Public Overage Fund), 128,520 (FLS X), 342,210 (FLS XI), and 597,210 (FLS XII).
Are there warrants disclosed and can they be exercised into common stock?
Yes. Prefunded warrants are disclosed (for example, 778,388 held by FLSPF). Each warrant has an exercise limitation so conversion cannot increase beneficial ownership above 9.99%.
Did the filing change previous ownership attributions?
The amendment corrects prior attributions and states that certain investment-committee members are not attributed beneficial ownership of securities directly held by specified funds.
What share counts were used to calculate the percentages in the filing?
Percentages are calculated using 50,268,758 shares outstanding as of May 9, 2025 and 11,735,565 shares sold in the issuer's public offering, as referenced in the filing.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, to receive support.
